

Vivir con VIH: comprender la experiencia de los pacientes y valorar la ciencia – Tveetorial #1

Referencias

Tweet 4

CDC. NCHHSTP AtlasPlus. Updated October 1, 2021. Accessed March 3, 2022.

<https://www.cdc.gov/nchhstp/atlas/index.htm>

Crepaz N, Hess KL, Purcell DW, Hall HI. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. *AIDS*. 2019;33(4):701-708.

doi:10.1097/QAD.0000000000002111

Tweet 5

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Updated January 20, 2022. Accessed February 4, 2022. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>

Tweet 6

CDC. Defining health disparities. Updated September 14, 2020. Accessed March 3, 2022.

<https://www.cdc.gov/nchhstp/healthdisparities/>

Sullivan PS, Satcher Johnson A, Pembleton ES, et al. Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. *Lancet*. 2021;397(10279):1095-1106. doi:10.1016/S0140-

6736(21)00395-0

Tweet 7

AIDSVu. AIDSVu Map. Accessed February 4, 2022. <https://map.aidsvu.org/map>

CDC. NCHHSTP AtlasPlus. Updated October 1, 2021. Accessed March 3, 2022.

<https://www.cdc.gov/nchhstp/atlas/index.htm>

Sullivan PS, Woodyatt C, Koski C, et al. A data visualization and dissemination resource to support HIV prevention and care at the local level: analysis and uses of the AIDSVu public data resource. *J Med Internet Res*. 2020;22(10):e23173. doi:10.2196/23173

Tweet 8

Singh S, Hu X, Hess K. Estimating the lifetime risk of a diagnosis of HIV infection in the United States.

Abstract 43 Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. [https://www.croiconference.org/abstract/estimating-the-lifetime-risk-of-a-diagnosis-](https://www.croiconference.org/abstract/estimating-the-lifetime-risk-of-a-diagnosis-of-hiv-infection-in-the-united-states/)

[of-hiv-infection-in-the-united-states/](https://www.croiconference.org/abstract/estimating-the-lifetime-risk-of-a-diagnosis-of-hiv-infection-in-the-united-states/)

Tweet 9

Clark H, Babu AS, Wiewel EW, Opoku J, Crepaz N. Diagnosed HIV infection in transgender adults and adolescents: results from the National HIV Surveillance System, 2009-2014. *AIDS Behav.* 2017;21(9):2774-2783. doi:10.1007/s10461-016-1656-7

Crepaz N, Hess KL, Purcell DW, Hall HI. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. *AIDS.* 2019;33(4):701-708. doi:10.1097/QAD.0000000000002111

Sullivan PS, Woodyatt C, Koski C, et al. A data visualization and dissemination resource to support HIV prevention and care at the local level: analysis and uses of the AIDSvu public data resource. *J Med Internet Res.* 2020;22(10):e23173. doi:10.2196/23173

Tweet 12

CDC. NCHHSTP AtlasPlus. Updated October 1, 2021. Accessed March 3, 2022.
<https://www.cdc.gov/nchhstp/atlas/index.htm>

Crepaz N, Hess KL, Purcell DW, Hall HI. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. *AIDS.* 2019;33(4):701-708. doi:10.1097/QAD.0000000000002111

Tweet 13

CDC. NCHHSTP AtlasPlus. Updated October 1, 2021. Accessed March 3, 2022.
<https://www.cdc.gov/nchhstp/atlas/index.htm>

Clark H, Babu AS, Wiewel EW, Opoku J, Crepaz N. Diagnosed HIV infection in transgender adults and adolescents: results from the national HIV Surveillance System, 2009-2014. *AIDS Behav.* 2017;21(9):2774-2783. doi:10.1007/s10461-016-1656-7

Crepaz N, Hess KL, Purcell DW, Hall HI. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. *AIDS.* 2019;33(4):701-708. doi:10.1097/QAD.0000000000002111

Lo CC, Runnels RC, Cheng TC. Racial/ethnic differences in HIV testing: an application of the health services utilization model. *SAGE Open Med.* 2018;6:2050312118783414. doi:10.1177/2050312118783414

Tweet 14

CDC. NCHHSTP AtlasPlus. Updated October 1, 2021. Accessed March 3, 2022.
<https://www.cdc.gov/nchhstp/atlas/index.htm>

Crepaz N, Hess KL, Purcell DW, Hall HI. Estimating national rates of HIV infection among MSM, persons who inject drugs, and heterosexuals in the United States. *AIDS.* 2019;33(4):701-708. doi:10.1097/QAD.0000000000002111

Tweet 15

Henkhaus ME, Hussen SA, Brown DN, et al. Barriers and facilitators to use of a mobile HIV care model to re-engage and retain out-of-care people living with HIV in Atlanta, Georgia. *PLoS One*. 2021;16(3):e0247328. doi:10.1371/journal.pone.0247328

Tweet 17

Henkhaus ME, Hussen SA, Brown DN, et al. Barriers and facilitators to use of a mobile HIV care model to re-engage and retain out-of-care people living with HIV in Atlanta, Georgia. *PLoS One*. 2021;16(3):e0247328. doi:10.1371/journal.pone.0247328

White E, Globberman J. Impact of community-based organizations for people living with HIV. Ontario HIV Treatment Network. Updated October 2015. Accessed March 9, 2022. <https://www.ohtn.on.ca/rapid-response-97-impact-of-community-based-organizations-for-people-living-with-hiv-2/>

Tweet 18

Grove M, Brown LL, Knudsen HK, Martin EG, Garner BR. Employing telehealth within HIV care: advantages, challenges, and recommendations. *AIDS*. 2021;35(8):1328-1330. doi:10.1097/QAD.0000000000002892

Taggart T, Grewe ME, Conserve DF, Gliwa C, Roman Isler M. Social media and HIV: a systematic review of uses of social media in HIV communication. *J Med Internet Res*. 2015;17(11):e248. doi:10.2196/jmir.4387

Tweet 19

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated January 20, 2022. Accessed February 4, 2022. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>

Tweet 21

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated January 20, 2022. Accessed February 4, 2022. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>

Tweet 22

Cabenuva. Prescribing information. ViiV Healthcare; 2022. Accessed April 5, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated January 20, 2022. Accessed February 4, 2022. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>

Glosario

3TC, lamivudine
ABC, abacavir
AI/AN, American Indian or Alaskan Native
ART, antiretroviral therapy
ARV, antiretroviral
BIC, bictegravir
DHHS, Department of Health and Human Services
DTG, dolutegravir
FTC, emtricitabine
HBV, hepatitis B virus
HCP, healthcare provider
Het, heterosexual
Hisp/Lat, Hispanic/Latinx
HLA-B*5701, human leukocyte antigen B * 5701 allele
IDU, injection drug use
LAI, long-acting injectable
MSM, men who have sex with men
NHOPI, Native Hawaiians and other Pacific Islanders
NTD, neural tube defect
RAL, raltegravir
RNA, ribonucleic acid
TAF, tenofovir alafenamide
TDF, tenofovir disoproxil fumarate
TM, transgender men
TW, transgender women
VIH, human immunodeficiency virus
w/, with